The results of China's development of new crown specific drugs are released: the efficacy is not inferior to Pfizer's Paxlovid, and the safety is higher
Author:Zheng Ning
publishing:2022-12-29 15:00renew:2022-12-29 15:00
The recent release of Pfizer's "new crown special drug" Paxlovid (Nimatevir/ritonavir tablets) in China has attracted various topics, and people are rushing to buy Pfizer's Indian generic drug.
According to the "Shangguan News" report, today (29th), the research results of the anti-coronavirus drug independently developed by China were released, and the efficacy is not inferior to Paxlovid, and even the safety is better.
The world's top medical journal "The New England Journal of Medicine (NEJM)" published online today the oral nucleoside anti-coronavirus drug VV116 compared with Paxlovid for severe patients with progression (including high risk factors for death) Phase III clinical research results of early treatment of patients with mild to moderate new coronary infection.
VV116 is an anti-coronavirus oral drug independently developed by Chinese scientists. The research is led by Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine. It is currently in the phase III clinical research stage of an international multi-center. It is also the first "head-to-head" phase III clinical study of a small molecule oral antiviral drug for Chinese patients with new crown infection during the Omicron epidemic.
Ning Guang, academician of the Chinese Academy of Engineering and president of Ruijin Hospital, said: "The results of this paper published in "NEJM" confirm that the clinical efficacy of VV116 is no less than that of Paxlovid. Our research not only contributes to the development and development of global anti-new crown small molecule drugs Clinical application provides valuable data and experience, and will also contribute to China's anti-epidemic cause."
It is reported that VV116 is an RdRp (ribonucleic acid polymerase) inhibitor that can inhibit the replication of the new coronavirus in the human body. It is composed of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Wuhan Institute of Virology, Chinese Academy of Sciences, Xinjiang Institute of Physics and Chemistry, Chinese Academy of Sciences, Central Asia Drug Research and Development Center of Chinese Academy of Sciences/China-Ukraine Medical Technology City (Ministry of Science and Technology "Belt and Road" Joint Laboratory), Lingang Experiment Jointly researched and developed by Wangshan Wangshui and Junshi Biotechnology. Junshi Biology and Wangshan Wangshui jointly undertake the clinical development and industrialization of the drug at the global level.
Domestic VV116 is safer than Pfizer PAXLOVID
In the study, 771 patients from seven designated hospitals in Shanghai were divided into VV116 group and Paxlovid group and received treatment respectively. The results of the study showed that among the tested patients, VV116 and Paxlovid achieved non-inferiority in the "time to sustained clinical recovery", and the median recovery time of the VV116 group was shorter than that of the Paxlovid group.
The VV116 group and the Paxlovid group performed similarly in terms of "time to disappearance of persistent symptoms" and "time to first negative nucleic acid", with a median time of 7 days. At each preset time point (days 5, 7, 10, 14, and 28), the proportion of patients with symptom relief in the VV116 group was higher than that in the Paxlovid group. No severe/critical illness or death occurred in the two groups of patients.
In addition, the incidence of adverse events in the VV116 group was lower than that in the Paxlovid group, and VV116 had fewer safety concerns than Paxlovid. It is worth noting that the possibility of interaction between VV116 and concomitant drugs is much smaller than that of Paxlovi
中國研製新冠特效藥結果發布：療效不輸輝瑞Paxlovid 安全性更高
近期關於輝瑞「新冠特效藥」Paxlovid（奈瑪特韋/利托那韋片）在中國的發售引來各種話題，還有民眾搶購輝瑞的印度仿製藥。據《上觀新聞》報道，今日
www-hk01-com.translate.goog
中國研製新冠特效藥結果發布：療效不輸輝瑞Paxlovid 安全性更高
近期關於輝瑞「新冠特效藥」Paxlovid（奈瑪特韋/利托那韋片）在中國的發售引來各種話題，還有民眾搶購輝瑞的印度仿製藥。據《上觀新聞》報道，今日
www-hk01-com.translate.goog
